Microbial cyclic β-(1 → 3),(1 → 6)-glucans as potential drug carriers: Interaction studies between cyclic β-glucans isolated from Bradyrhizobium japonicum and betulinic acid

Kambhampati, Naga Sai Visweswar; Kar, Swayamsiddha; Pinnepalli, Sai Siva Kumar; Janardhana, Ch.; Doble, Mukesh

doi:10.1016/j.saa.2018.05.106

Cited by 7 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These polysaccharides are cell surface carbohydrates, which are considered major cell envelope constituents. The cyclic β-(1,3;1,6)-glucans are promising encapsulating agents that could be used as drug delivery carriers for antitumor drugs such as betulinic acid (BA) [ 24 ].…”

Section: Cyclic β-(13;16)-glucansmentioning

confidence: 99%

Potential promising anticancer applications of β-glucans: a review

Noorbakhsh Varnosfaderani,

Ebrahimzadeh,

Akbari Oryani

et al. 2024

Bioscience Reports

View full text Add to dashboard Cite

β-Glucans are valuable functional polysaccharides distributed in nature, especially in the cell walls of fungi, yeasts, bacteria, and cereals. The unique features of β-glucans, such as water solubility, viscosity, molecular weight, and so on, have rendered them to be broadly applied in various food systems as well as in medicine to improve human health. Moreover, inhibition of cancer development could be achieved by an increase in immune system activity via β-glucans. β-glucans, which are part of a class of naturally occurring substances known as biological response modifiers (BRMs), have also shown evidence of being anti-tumorogenic, anti-cytotoxic, and anti-mutagenic. These properties make them attractive candidates for use as pharmaceutical health promoters. Along these lines, they could activate particular proteins or receptors, like lactosylceramide (LacCer), Dickin-1, complement receptor 3 (CR3), scavenge receptors (SR), and the toll-like receptor (TLR). This would cause the release of cytokines, which would then activate other antitumor immune cells, like macrophages stimulating neutrophils and monocytes. These cells are biased toward pro-inflammatory cytokine synthesis and phagocytosis enhancing the elicited immunological responses. So, to consider the importance of β-glucans, the present review introduces the structure characteristics, biological activity, and antitumor functions of fungal β-glucans, as well as their application.

show abstract

Section: Cyclic β-(13;16)-glucansmentioning

confidence: 99%

Potential promising anticancer applications of β-glucans: a review

Noorbakhsh Varnosfaderani,

Ebrahimzadeh,

Akbari Oryani

et al. 2024

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…The molecular weight of these polymers, ranges between 1 to 6 kDa, with the degree of polymerization from 14 to 28. Each ring size of the CβG exists as a mixture of conformations that have cavities of variable size and polarity [8, 9, 10, 11]. As a result, they form inclusion complexes with both polar and nonpolar compounds including poorly water-soluble molecules such as mefenamic acid, vitamins, phenylbutazone, indomethacin, steroids, paclitaxel, vitamins, ergosterol, amphotericin B, flurbiprofen, luteolin and betulinic acid [8, 9].…”

Section: Introductionmentioning

confidence: 99%

“…Each ring size of the CβG exists as a mixture of conformations that have cavities of variable size and polarity [8, 9, 10, 11]. As a result, they form inclusion complexes with both polar and nonpolar compounds including poorly water-soluble molecules such as mefenamic acid, vitamins, phenylbutazone, indomethacin, steroids, paclitaxel, vitamins, ergosterol, amphotericin B, flurbiprofen, luteolin and betulinic acid [8, 9]. CβG had been reported to have good encapsulation efficiency for various drugs (with 85–99 % efficiency) including dexamethasone, umbelliferone, curcumin, 6-methylcoumarin, 4-hydroxycoumarin and 4 methyl umbelliferone [12].…”

Section: Introductionmentioning

confidence: 99%

Cyclic β-(1, 2)-glucan blended poly DL lactic co glycolic acid (PLGA 10:90) nanoparticles for drug delivery

Venkatachalam

Venkatesan

Ganesan

et al. 2019

Heliyon

Self Cite

View full text Add to dashboard Cite

Our group had previously reported the encapsulation efficiency of cyclic β-(1, 2)-glucan for various drugs. The current study is aimed at evaluating the use of glucan as a drug carrier system by blending with poly lactic-co- glycolic acid (L:G = 10:90). Nanoparticles of glucan (0.5, 5, 10 and 20 wt %) blended with PLGA and gentamicin were synthesized. Encapsulation efficiency was higher for the blends (93% with 20 wt % of glucan) than the PLGA alone (79.8%). The presence of glucan enhanced both the biodegradability, and biocompatibility of PLGA. Degradation of the nanoparticles in vitro, was autocatalytic with an initial burst release of active drug and the release profile was modeled using the Korsmeyer-Peppas scheme. In vivo studies indicated that the drug released from the blends had high volume of distribution, and greater clearance from the system. Pharmacokinetics of the drug was predicted using a double exponential decay model. Blending with PLGA improved the drug release characteristics of the cyclic β-(1, 2)-glucan.

show abstract